نتائج البحث - "Camidge, D. Ross"

1

دورية أكاديمية

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib

المؤلفون: Horn, Leora, Gettinger, Scott, Camidge, D. Ross, Smit, Egbert F., Janjigian, Yelena Y., Miller, Vincent A., Pao, William, Freiwald, Matthias, Fan, Jean, Wang, Bushi, Chand, Vikram K., Groen, Harry J. M.

المصدر: Horn , L , Gettinger , S , Camidge , D R , Smit , E F , Janjigian , Y Y , Miller , V A , Pao , W , Freiwald , M , Fan , J , Wang , B , Chand , V K & Groen , H J M 2017 , ' Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib ' , Lung Cancer , vol. 113 , pp. 51-58 . https://doi.org/10.1016/j.lungcan.2017.08.014Test

مصطلحات موضوعية: Phase Ib, Afatinib, Cetuximab, NSCLC, EGFR, TYROSINE KINASE INHIBITORS, RANDOMIZED PHASE-3 TRIAL, GROWTH-FACTOR RECEPTOR, 1ST-LINE TREATMENT, OPEN-LABEL, CHEMOTHERAPY, ADENOCARCINOMA, HER2, MULTICENTER, MECHANISM

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/3a825068-c6df-49d0-ad95-42dc73e4cc9eTest

الإتاحة: https://doi.org/10.1016/j.lungcan.2017.08.014Test
https://hdl.handle.net/11370/3a825068-c6df-49d0-ad95-42dc73e4cc9eTest
https://research.rug.nl/en/publications/3a825068-c6df-49d0-ad95-42dc73e4cc9eTest
https://pure.rug.nl/ws/files/50615255/1_s2.0_S0169500217304877_main.pdfTest

View record in BASE

2

دورية أكاديمية

Indirect comparisons of brigatinib and alectinib for front-line -positive non-small-cell lung cancer.

المؤلفون: Reckamp, Karen L, Lin, Huamao M, Cranmer, Holly, Wu, Yanyu, Zhang, Pingkuan, Walton, Laura J, Kay, Stephen, Cichewicz, Allie, Neupane, Binod, Fahrbach, Kyle, Popat, Sanjay, Camidge, D Ross

المصدر: Future Oncology; Jul2022, Vol. 18 Issue 20, p2499-2510, 12p

مصطلحات موضوعية: LUNG cancer, DISEASE progression, PROTEIN kinase inhibitors, HETEROCYCLIC compounds, ORGANOPHOSPHORUS compounds, LUNG tumors, PIPERIDINE, RESEARCH funding

3

دورية أكاديمية

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteria

المؤلفون: Gandhi, Leena, Ou, Sai-Hong Ignatius, Shaw, Alice T., Barlesi, Fabrice, Dingemans, Anne-Marie C., Kim, Dong-Wan, Camidge, D. Ross, Hughes, Brett G. M., Yang, James C. -H., de Castro, Javier, Crino, Lucio, Lena, Herve, Do, Pascal, Golding, Sophie, Bordogna, Walter, Zeaiter, Ali, Kotb, Ahmed, Gadgeel, Shirish

مصطلحات موضوعية: Alectinib, CNS metastases, NSCLC, RANO-HGG, RECIST, 1306 Cancer Research, 2730 Oncology

العلاقة: orcid:0000-0002-1811-0537

الإتاحة: https://doi.org/10.1016/j.ejca.2017.05.019Test
https://espace.library.uq.edu.au/view/UQ:682068Test

View record in BASE

4

دورية أكاديمية

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive non-small-cell lung cancer:Comparison of RECIST 1.1 and RANO-HGG criteria

المؤلفون: Gandhi, Leena, Ou, Sai-Hong Ignatius, Shaw, Alice T., Barlesi, Fabrice, Dingemans, Anne-Marie C., Kim, Dong-Wan, Camidge, D. Ross, Hughes, Brett G. M., Yang, James C. -H., de Castro, Javier, Crino, Lucio, Lena, Herve, Do, Pascal, Golding, Sophie, Bordogna, Walter, Zeaiter, Ali, Kotb, Ahmed, Gadgeel, Shirish

المصدر: Gandhi , L , Ou , S-H I , Shaw , A T , Barlesi , F , Dingemans , A-M C , Kim , D-W , Camidge , D R , Hughes , B G M , Yang , J C -H , de Castro , J , Crino , L , Lena , H , Do , P , Golding , S , Bordogna , W , Zeaiter , A , Kotb , A & Gadgeel , S 2017 , ' Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive non-small-cell lung cancer : ....

مصطلحات موضوعية: Alectinib, CNS metastases, NSCLC, RANO-HGG, RECIST, RESPONSE ASSESSMENT CRITERIA, BRAIN METASTASES, PSEUDOPROGRESSION, CHEMOTHERAPY, RADIATION, NECROSIS, DISEASE

الإتاحة: https://doi.org/10.1016/j.ejca.2017.05.019Test
https://cris.maastrichtuniversity.nl/en/publications/e67fa360-3f1a-4219-ab18-041e57433005Test

View record in BASE

5

دورية أكاديمية

Brigatinib in Crizotinib-Refractory ALK plus NSCLC:Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial

المصدر: Camidge , D R , Tiseo , M , Ahn , M-J , Reckamp , K , Hansen , K , Kim , S-W , Huber , R , West , H , Groen , H , Hochmair , M , Leighl , N , Gettinger , S , Langer , C , Paz-Ares , L , Smit , E , Kim , E , Reichmann , W , Clackson , T , Kerstein , D , Haluska , F & Kim , D-W 2017 , ' Brigatinib in Crizotinib-Refractory ALK plus NSCLC : Central Assessment and Updates from ....

مصطلحات موضوعية: ALK, brigatinib, NSCLC, TKI

الإتاحة: http://hdl.handle.net/11370/6ceced4d-153a-454b-9829-1eac588a034dTest
https://research.rug.nl/en/publications/brigatinib-in-crizotinibrefractory-alk-plusTest-nsclc(6ceced4d-153a-454b-9829-1eac588a034d).html

View record in BASE